美股異動 | Ocugen(OCGN.US)跌14.42% 將額外出售至15%的普通股
格隆匯2月23日丨Ocugen(OCGN.US)跌14.42%,報3.62美元。該公司昨日宣佈進行普通股的公開發行,預計將向承銷商授予30天的選擇權,以購買公開發行中出售的普通股至多15%的股份。此次發行的股票都由Ocugen出售。該公司打算將籌集的資金用於常規公司經營、資本支出、營運資本以及行政費用。該公司的股價在2月22日宣佈FDA解除了對該公司在美國的新冠肺炎疫苗研究的臨牀實驗禁止令後上漲22.25%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.